The involvement of inflammation in cardiovascular disease was first recognized more than three decades ago, when systemic inflammatory markers (specifically the acute‐phase proteins C‐reactive protein (CRP) and serum amyloid A) were associated with adverse outcomes, initially in patients with acute coronary syndromes [1] and subsequently in apparently healthy men [2]. The gene discussed is CRP; the disease is cardiovascular disorder.